AN Alzheimer’s drug which has been rejected for NHS use can slow disease progression by eight years, researchers have claimed ...

Researchers found long-term treatment could delay progression from mild cognitive impairment to moderate Alzheimer’s disease ...

High-sensitivity C-reactive protein (CRP) decreased significantly in the semaglutide group, with estimated treatment ratios ...

Lecanemab is licensed for use in the UK but the spending watchdog deemed the benefits shown in clinical trials were 'too ...

A deep analysis of semaglutide’s phase 3 AD trials shows no cognitive or functional benefit despite biomarker gains, yet ...

We came across a bullish thesis on Eli Lilly and Company on Pebble Bites’s Substack by Christina Gan. In this article, we ...

An Alzheimer’s drug which has been rejected for NHS use can slow disease progression by eight years, researchers have claimed ...

Home Instead chief executive Martin Jones said: “Dementia has now eclipsed cancer as our greatest health fear for the future.

Early evidence links some Alzheimer’s Disease medications to small cognitive gains in children with autism and low IQ, ...

A new Australian biotech, Evinco Therapeutics, has launched in Melbourne to advance immune-based treatments for Alzheimer’s ...

American drugmaker Eli Lilly has said it will not restart paused investment in the UK until it sees changes to the types of ...

People  living with dementia in Fermanagh embraced “a unique and wonderful opportunity” to meet with a renowned campaigner.